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Chap te r  B
Summary and discussion
This thesis describes: 1) the development of a new and reliable animal model for
in-stent restenosis (ISR), which enables thorough pathophysiological stent
research and the screening of anti-restenotic therapies, 2) the necessity for addi-
tional physiological anti-restenotic strategies and 3) the evaluation of endothelial
function improvement, as a method for more physiological anti-restenotic therapy.
In Chapter 2, elaborate descriptions of the pathophysiological process of ISR and
the role of the renin-angiotensin system (RAS) in ISR are provided. Restenosis is
the arterial healing process as seen after vascular injury inflicted during percuta-
neous transluminal coronary angioplasty (PTCA). Restenosis after balloon angio-
plasty is caused by elastic recoil, negative remodelling and neointimal formation.
Stent implantation prohibits virtually all elastic recoil and negative remodelling
after PTCA. However, restenosis still occurs, now mainly due to excessive neointi-
mal formation. Neointimal formation ensues from endothelial denudation and
deep vascular injury, which result in subsequent thrombus formation, inflamma-
tion and smooth muscle cell proliferation.
ISR is currently effectively prevented by drug-eluting stents (DES). These stents
coated with strong anti-proliferative agents potently inhibit smooth muscle cell
proliferation and consequently ISR. However, due to findings such as incomplete
re-endothelialisation, delayed vascular healing, late thrombosis and hypersensi-
tivity reactions after DES implantation, major concerns with regard to the late
effects of these stents have emerged. Therefore, there is an increasing interest for
more physiological anti-restenotic strategies.
The systemic use of RAS intervention in cardiovascular disease is widespread and
rather safe. The RAS plays a role in the pathophysiology of ISR. RAS intervention
by means of angiotensin-converting errzyrrre (ACE) inhibition, angiotensin II type
1 (AT') receptor blockade or angiotensin-(1-7) (Ang-(1-7)) might be an appealing
method for prevention of ISR in a physiological manner.
The use of ACE inhibitors as anti-restenotic therapy is disputable. ACE inhibitors
are probably ineffective due to the need for high dosing to inhibit tissue ACE and
alternative angiotensin II forming pathways. The effects of alternative
angiotensin II formation can be avoided by means of AT' receptor blockade. AT'
receptor blockers have been proven to be effective in the prevention of ISR in ani-
mal models and in humans. Combination of an ACE inhibitor and an AT1 receptor
blocker might be even more effective, as a consequence of additional bradykinin-
dependent nitric oxide formation. Recently, Ang-(1-7) has also been shown effective
in preventing restenosis after vascular injury and stent implantation. F uture
experiments concerning RAS intervention to prevent ISR in a physiological man-
ner, should focus on the local application of ATr r€c€ptor blockers, combination
therapy and Ang-(l-7), by means of DES.
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Rat abdomínal aorta stenting model
Chapter 3 describes the development of a new animal model of ISR. Coronary
stents were implanted in the abdominal aorta of the rat. After 1, 3, 7, 28 and 56
days the rats were sacrificed and the pathophysiological mechanisms of ISR were
evaluated. Furthermore, a known anti-restenotic stent was implanted to examine
the predictive value of this model. Surgical procedures were generally well toler-
ated by the animals. Neointimal measurements such as, neointimal area, neointi-
mal thickness and percentage stenosis increased up to 28 days after stent place-
ment. Thereafter, a slight decrease in neointimal parameters was observed.
Moreover, strong positive linear correlations were observed. between the mean
injury score and neointimal measurements. These patterns of neointimal forma-
tion are similar as seen in the well-established pig coronary and the rabbit iliac
artery ISR models.
As for pathophysiological mechanisms of ISR, we observed focal thrombus forma-
tion in the early stages of this model. Adhesion and inÍiltration of leukocytes
occurred as soon as 1 day after stenting and they peaked after 3 and 7 days, respec-
tively. The inflammatory response was virtually absent after 28 days. In the late
stages of this model a clear neointima was present, which consisted of smooth
muscle-like cells and extracellular matrix. These vascular responses develop sim-
ilar as in other ISR models.
Finally, we found a reduction in neointimal formation after implantation of a
known anti-restenotic stent. Thus, the rat abdominal aorta stenting model is fea-
sible, it displays similar vascular responses to stent implantation as seen in the
established pig and rabbit ISR models and it is useful for testing anti-restenotic
agents and intra-vascular devices.
Preclinical animal models of ISR are important but imperfect standards. Presently
available ISR models are the pig coronary artery and rabbit iliac artery stent mod-
els. These models have some drawbacks. A combination of radiological and surgi-
cal utilities is required, most animal facilities have limited housing capacity for pig
and rabbits and the costs for purchase are high. A simple, inexpensive, rapid and
accurate preclinical model would be useful '. In the rat abdominal aorta stenting
model only a surgical microscope and mainstream surgical equipment are
required. The housing capacity for rat is less limited and the costs for purchase are
low. The applicability of the rat model to test anti-restenotic therapies was shown
by the effective inhibition of neointimal formation by rapamycin-eluting stents.
Thus the rat abdominal aorta stenting model is a simple, inexpensive, rapid and
accurate preclinical model for ISR.
Insights in pathophysiological mechanisms of ISR are essential for the develop-
ment of new anti-restenotic therapies. Since only a limited number of antibodies to
cellular proteins and transgenic and knockout strains are available, possibilities
to perform pathophysiological experiments in the pig and rabbit models are
restricted. Many antibodies as well as transgenic diabetic and hypertensive
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strains are available in rats. Moreover, knockout strains are becoming available'.
Consequently, the rat abdominal aorta stenting model enables thorough patho-
physiological re search.
Therefore, the rat abdominal aorta stenting model is a simple, inexpensive, rapid
and accurate preclinical model for in-stent restenosis, which enables thorough
pathophysiological stent research and the screening of anti-restenotic therapies.
Drug-elutíng stents and the necessity of physiologícal treatment
The effects of paclitaxel-eluting TAXUS stent implantation in absence of anti-
platelet therapy are specified in Chapter 4.In the absence of anti-platelet ther-
apy, paclitaxel-eluting stent placement resulted in signs of delayed healing, such
as fibrin deposition and intra-intima hemorrhage. As expected, paclitaxel-eluting
stent implantation resulted in a decrement in neointimal cell density. Further-
more, measurements of neointimal area showed an increase after paclitaxel-elut-
ing stent implantation as compared to bare metal stent placement. This empha-
sises the necessity of anti-platelet therapy after implantation of the present
generation DES.
Presently, ISR is effectively controlled in clinical practice by DES. Stents coated
with paclitaxel strongly inhibit smooth muscle cell proliferation and subsequent
neointimal formation'''n. Nevertheless, paclitaxel-eluting stents have potential
long-term adverse sequelae. Recent studies suggest that paclitaxel-eluting stent
show incomplete re-endothelialisation, late stent thrombosis and delayed vascular
healing 5 e. These findings of delayed healing after paclitaxel-eluting stent implan-
tation are confirmed by our results.
Delayed re-endothelialisation may lead to increased susceptibility for late throm-
bosis after discontinuation of anti-platelet therapy. F urthermore, in the absence of
anti-platelet therapy delayed re-endothelialisation after paclitaxel-eluting stent
implantation may result in excessive adhesion of platelets and inflammatory cells
to the injured vascular wall, with subsequent increased neointimal formation.
Delayed re-endothelialisation may explain why paclitaxel-eluting stent placement
in the absence of anti-platelet therapy results in exaggerated neointimal forma-
tion. This emphasises the importance of anti-platelet therapy after paclitaxel-elut-
ing stent implantation. More importantly, incomplete re-endothelialisation after
stenting is precarious. This underlines the necessity of optimisation of current
anti-restenotic strategies and development of additional more physiological anti-
restenotic strategies.
Recouery of systemic endothelial function and ISR
In Chapters 5, 6 and 7 t}re influence of improvement of systemic endothelial
function on ISR is illustrated. Chapter 5 describes that stent implantation in the
rat abdominal aorta resulted in a substantial deterioration of systemic endothelial
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of systemic endothelial function. Moreover, Ang-(1-7) attenuated neointimal for-
mation after stenting in the rat abdominal aorta. In Chapter 6 the long-acting
erythropoietin (EPO) analogue, darbepoetin also was shown to improve systemic
endothelial function. However, with this drug, recovery of endothelial function was
not accompanied by a reduction in the volume of neointimal tissue growth. A
detailed description of the relationship between systemic endothelial function and
neointimal formation is provided rn Chapter 7. The effect of stenting on systemic
endothelial function and its different mediators was examined. Concurrently, the
effects of Ang-(1-7) and darbepoetin treatment were studied. Finally, correlations
between systemic endothelial function were determined. Stent placement
resulted in a strong impairment of systemic endothelial function. This impairment
was characterised by a major reduction in nitric oxide (NO)-dependent vasodila-
tion, which was partly compensated by an increase in endothelial derived hyper-
polarizing factor (trDHF)-dependent vasorelaxation. The Ang-Í-7) induced recov-
ery of systemic endothelial function was brought about by an increase in
prostaglandin (PG)- and EDHF-dependent vasodilation. darbepoetin also
improved systemic endothelial function after stent placement. However, this
increase in endothelium-dependent vasorelaxation, was mainly due to a recovery
of NO-dependent vasodilation. As darbepoetin-dependent recovery of systemic
endothelial function was not accompanied by a reduction in neointimal formation,
a relationship between systemic endothelial function and ISR seems unlikely. To
strengthen this observation, correlations between systemic endothelial function
and neointimal measurements were also absent.
Stent implantation results in severe endothelial disruption 'o'". Stenting also
induces pronounced endothelial dysfunction ". Moreover, a decreased systemic
endothelial function is associated with the occurrence of ISR ". Improvement of
the systemic endothelial function results in release of potential anti-restenotic
substances, like NO, PG and trDHF. Thus, systemic endothelial enhancement
might reduce ISR. Arg-(t-Z) attenuates neointimal formation accompanied with a
recovery of systemic endothelial function. Contrarily, darbepoetin also improves
systemic endothelial function, however it does not influence neointimal formation.
This taken together with the absence of correlations between endothelial function
and neointimal measurements implies that there is no direct relation between sys-
temic endothelial function and ISR. Therefore, experimental anti-restenotic
strategies should restore the endothelium and its function, and in addition smooth
muscle cell proliferation should be inhibited.
Future dírections
For the development of future anti-restenotic regimes, elucidation of pathophysio-
logical mechanisms of ISR is indispensable. The rat abdominal aorta stenting
model enables thorough pathophysiological experiments. The usefulness of this
model for explaining pathophysiological processes is already demonstrated by
' 1 1 1
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Zhou et al ". Considering that this rat model is simple, rapid, inexpensive and
accurate, the application of this model can become widespread. Thus, the rat
abdominal aorta stenting model might make a substantial contribution to insights
into pathophysiological processes of ISR and the development of future anti-
restenotic therapies.
As for the currently available anti-restenotic strategies, the rapamycin- and pacli-
taxel-eluting stents, their long-term safety profile has to be determined. Presently,
reports of incomplete re-endothelialisation, late thrombosis and delayed vascular
healing emphasise the necessity for the development of more physiological anti-
restenotic therapies. Physiological therapies should aim to act through the normal
arterial healing process.
Improvement of systemic endothelial function may be an attractive alternative
physiological anti-restenotic therapy. However, we demonstrated that improve-
ment of the systemic endothelial function alone is not sufficient to inhibit neointi-
mal formation. Previously, it was shown that promotion of local re-endothelialisa-
tion by vascular endothelial growth factor (VEGF) inhibits neointimal formation
"''5. The latter observation suggests that promotion of re-endothelialisation is
effective for prevention of ISR. Moreover, it suggests that there is dissociation
between systemic endothelial function and re-endothelialisation, since systemic
endothelial function improvement does not prevent neointimal formation. How-
ever, VEGF also appears to have a direct inhibitory effect on vascular smooth mus-
cle cells '6. Thus the problem whether re-endothelialisation alone is suÍficient to
inhibit ISR, remains unresolved. Stents coated with antibodies to CDB4 receptors
on circulating endothelial cells have been developed 
". The results of experiments
with these stents will give us more insight in this important controversy.
As for potential future physiological anti-restenotic substances, Ang-(t-Z) is an
attractive option. Firstl;2, Ang-(1-7) has beneficial effects on the endothelium 18,1e.
Secondly, Ang-(1-7) inhibits smooth muscle cell proliferation 20. Moreover, we have
shown that systemic treatment with Ang-(t-7) attenuates neointimal formation.
As systemic Ang-( l-7) treatment is no option, an Ang-(l-Z)-eluting stent is a poten-
tial future solution for the problem of ISR.
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